Download PDFPDF
An association between infantile haemangiomas and erythropoietin treatment in preterm infants
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    High dose erythropoietin in preterm infants for neuroprotection does not increase the risk for haemangioma
    • Hans Ulrich Bucher, Full Professor
    • Other Contributors:
      • Alois Tschopp, Brigitte Koller, Jean-Claude Fauchere on behalf of the Swiss EPO Neuroprotection Trial Group

    Based on a retrospective study, Doege et al. reported an increased incidence of haemangioma after treatment with erythropoietin. To verify these results, we did an interim analysis in an on-going prospective randomized placebo-controlled multicentre trial comparing high dose recombinant human erythropoietin (rhEpo) 3,000 U/kg body weight with NaCl 0.9% intravenously at 3, 12-18 and 36-42 hours after birth (NCT00413946)....

    Show More
    Conflict of Interest:
    None declared.